Syncona (SYNC) H2 2026 earnings summary

Executive summary

• NAV per share remained roughly flat for the year, with the life science portfolio marginally positive due to strong performance at Beacon, offset by write-downs at Kesmalea and CRT Pioneer Fund, and volatility in Autolus share price.

• Portfolio is 86% weighted toward commercial and clinical-stage companies, with strong clinical and operational progress, including research milestones and collaborations.

• GBP 198 million in available capital supports late-stage portfolio advancement and liquidity, with a target to return at least GBP 250 million to shareholders.

• Strategic focus on value realization, with strong shareholder support (90%) for proposals and an aligned incentive scheme.

• Approved a new investment policy and incentive arrangements to align management with shareholder outcomes.

Financial highlights

• Net Asset Value (NAV) at £1.0bn (171p per share), representing a (0.2)% return for the year.

• Life Science Portfolio delivered a 1.7% return, driven by a write-up of Beacon after Series C financing, offset by partial write-downs in Kesmalea and CRT Pioneer Fund, and volatility in Autolus share price.

• GBP 81 million deployed during the year, with 84% allocated to late-stage and clinical assets.

• GBP 8.1 million invested in two early-stage opportunities, RIME and ALTx, via the Slingshot accelerator.

• GBP 25 million deployed post year-end into Spur and Resolution.

Outlook and guidance

• Focused on delivering a minimum of GBP 250 million in returns to shareholders from private company exits.

• Eight key value inflection points (KVIPs) identified, with four expected in calendar year 2026, supporting potential NAV growth.

• Fully funded to deliver on all KVIPs, with capital deployment weighted toward late-stage and clinical-stage assets.

• Continued emphasis on late-stage asset development, M&A, and strategic partnerships.